Valo Therapeutics Acquires University of Helsinki’s PeptiBAC Cancer and Infectious Disease Vaccination Technology

Helsinki, Finland, 19 April 2021: Valo Therapeutics Limited (Valo Tx), the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced the acquisition of intellectual property rights for the proprietary ‘PeptiBAC’ technology from the University of Helsinki, Finland.

Read full release here.